Liver cancer
Results
Phase 1/2
This trial looked at tefinostat for the most common type of liver cancer called hepatocellular carcinoma (HCC).
This trial was open for people to join between 2012 and 2017. The team reported the results in 2019.
Cancer Research UK supported this trial.
Recruitment start: 24 December 2012
Recruitment end: 11 May 2017
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr David Propper
Cancer Research UK
Chroma Therapeutics
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Queen Mary University of London
This is Cancer Research UK trial number CRUKD/12/011.
Last reviewed: 28 September 2021
CRUK internal database number: 9047